Modulation of adjuvant arthritis in the rat by 2-methoxyestradiol: An effect independent of an anti-angiogenic action

International Immunopharmacology

Volumn 8, Issue 5, 2008, Pages 708-716

  Issekutz, Andrew C ^a   Sapru, Kusum ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Angiogenesis; Anti inflammatory; Immunomodulation

Indexed keywords

2 METHOXYESTRADIOL; COMPLEMENT COMPONENT C5A; CONCANAVALIN A; LIPOPOLYSACCHARIDE; MITOGENIC AGENT; MYCOBACTERIUM ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTHRITIS; ARTICLE; CARTILAGE; CELL INFILTRATION; CELL MIGRATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MECHANISM; EX VIVO STUDY; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNIZATION; INFLAMMATION; ISOTOPE LABELING; LEUKOCYTE; LYMPHOCYTE; LYMPHOID HYPERPLASIA; MALE; MYCOBACTERIUM BUTYRICUM; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RAT; SCORING SYSTEM; SPLENOMEGALY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIGENS, BACTERIAL; ARTHRITIS, EXPERIMENTAL; CARTILAGE; CELL PROLIFERATION; DERMATITIS; ENDOTHELIAL CELLS; ESTRADIOL; LYMPHOCYTES; MALE; MITOGENS; NEUTROPHILS; RATS; RATS, INBRED LEW; SPLEEN; SYNOVIAL FLUID;

EID: 41149126578     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2008.01.016     Document Type: Article

References (37)

1. Fournier C. Where do T cells stand in rheumatoid arthritis?. Joint Bone Spine 72 (2005) 527-532
2. Kannan K., Ortmann R.A., and Kimpel D. Animal models of rheumatoid arthritis and their relevance to human disease. Pathophysiology 12 (2005) 167-181
3. Firestein G.S. Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. J Clin Rheumatol 11 (2005) S39-S44
4. Breedveld F.C., and Trentham D.E. Progress in the understanding of inducible models of chronic arthritis. Rheum Dis Clin North Am 13 (1987) 531-544
5. Taurog J.D., Argentieri D.C., and McReynolds R.A. Adjuvant arthritis. Methods Enzymol 162 (1988) 339-355
6. Findlay D.M., and Haynes D.R. Mechanisms of bone loss in rheumatoid arthritis. Mod Rheumatol 15 (2005) 232-240
7. Rannou F., Francois M., Corvol M.T., and Berenbaum F. Cartilage breakdown in rheumatoid arthritis. Joint Bone Spine 73 (2006) 29-36
8. Koch A.E. Angiogenesis as a target in rheumatoid arthritis. Ann Rheum Dis 62 Suppl 2 (2003) ii60-ii67
9. Maruotti N., Cantatore F.P., Crivellato E., Vacca A., and Ribatti D. Angiogenesis in rheumatoid arthritis. Histol Histopathol 21 (2006) 557-566
10. Lainer D.T., and Brahn E. New antiangiogenic strategies for the treatment of proliferative synovitis. Expert Opin Investig Drugs 14 (2005) 1-17
11. Yue L., Wang H., Liu L.H., Shen Y.X., and Wei W. Anti-adjuvant arthritis of recombinant human endostatin in rats via inhibition of angiogenesis and proinflammatory factors. Acta Pharmacol Sin 25 (2004) 1182-1185
12. Oliver S.J., Banquerigo M.L., and Brahn E. Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol. Cell Immunol 157 (1994) 291-299
13. Storgard C.M., Stupack D.G., Jonczyk A., Goodman S.L., Fox R.I., and Cheresh D.A. Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. J Clin Invest 103 (1999) 47-54
14. Fotsis T., Zhang Y., Pepper M.S., et al. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 368 (1994) 237-239
15. Ho Y.T., Newman S.P., Purohit A., Leese M.P., Potter B.V., and Reed M.J. The effects of 2-methoxy oestrogens and their sulphamoylated derivatives in conjunction with TNF-alpha on endothelial and fibroblast cell growth, morphology and apoptosis. J Steroid Biochem Mol Biol 86 (2003) 189-196
16. Tsukamoto A., Kaneko Y., Yoshida T., Han K., Ichinose M., and Kimura S. 2-Methoxyestradiol, an endogenous metabolite of estrogen, enhances apoptosis and beta-galactosidase expression in vascular endothelial cells. Biochem Biophys Res Commun 248 (1998) 9-12
17. Pribluda V.S., Gubish Jr. E.R., Lavallee T.M., Treston A., Swartz G.M., and Green S.J. 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev 19 (2000) 173-179
18. Schumacher G., and Neuhaus P. The physiological estrogen metabolite 2-methoxyestradiol reduces tumor growth and induces apoptosis in human solid tumors. J Cancer Res Clin Oncol 127 (2001) 405-410
19. Schumacher G., and Neuhaus P. 2-Methoxyestradiol-a new compound for cancer treatment. Dtsch Med Wochenschr 131 (2006) 825-830
20. Dahut W.L., Lakhani N.J., Gulley J.L., et al. Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther 5 (2006) 22-27
21. Josefsson E., and Tarkowski A. Suppression of type II collagen-induced arthritis by the endogenous estrogen metabolite 2-methoxyestradiol. Arthritis Rheum 40 (1997) 154-163
22. Issekutz A.C., and Issekutz T.B. Quantitation and kinetics of polymorphonuclear leukocyte and lymphocyte accumulation in joints during adjuvant arthritis in the rat. Lab Invest 64 (1991) 656-663
23. Issekutz A.C., Mu J.Y., Liu G., Melrose J., and Berg E.L. E-selectin, but not P-selectin, is required for development of adjuvant-induced arthritis in the rat. Arthritis Rheum 44 (2001) 1428-1437
24. Zhang H., and Issekutz A.C. Growth factor regulation of neutrophil-endothelial cell interactions. J Leukoc Biol 70 (2001) 225-232
25. Issekutz A.C., Meager A., Otterness I., and Issekutz T.B. The role of tumour necrosis factor-alpha and IL-1 in polymorphonuclear leucocyte and T lymphocyte recruitment to joint inflammation in adjuvant arthritis. Clin Exp Immunol 97 (1994) 26-32
26. Kurokawa A, Azuma K, Mita T, et al. 2-Methoxyestradiol reduces monocyte adhesion to aortic endothelial cells in ovariectomized rats. Endocr J in press (Electronic publication ahead of print).
27. Tofovic S.P., Dubey R., Salah E.M., and Jackson E.K. 2-Hydroxyestradiol attenuates renal disease in chronic puromycin aminonucleoside nephropathy. J Am Soc Nephrol 13 (2002) 2737-2747
28. Tofovic S.P., Zhang X., Jackson E.K., Dacic S., and Petrusevska G. 2-Methoxyestradiol mediates the protective effects of estradiol in monocrotaline-induced pulmonary hypertension. Vascul Pharmacol 45 (2006) 358-367
29. Tofovic S.P., Salah E.M., Dubey R.K., Melhem M.F., and Jackson E.K. Estradiol metabolites attenuate renal and cardiovascular injury induced by chronic nitric oxide synthase inhibition. J Cardiovasc Pharmacol 46 (2005) 25-35
30. Zhang X., Jia Y., Jackson E.K., and Tofovic S.P. 2-Methoxyestradiol and 2-ethoxyestradiol retard the progression of renal disease in aged, obese, diabetic ZSF1 rats. J Cardiovasc Pharmacol 49 (2007) 56-63
31. Mooberry S.L. New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent. Curr Opin Oncol 15 (2003) 425-430
32. LaVallee T.M., Zhan X.H., Johnson M.S., et al. 2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Cancer Res 63 (2003) 468-475
33. Wood L., Leese M.P., Mouzakiti A., et al. 2-MeOE2bisMATE induces caspase-dependent apoptosis in CAL51 breast cancer cells and overcomes resistance to TRAIL via cooperative activation of caspases. Apoptosis 9 (2004) 323-332
34. Djavaheri-Mergny M., Wietzerbin J., Rouillard D., and Besancon F. TNFalpha potentiates 2-methoxyestradiol-induced mitochondrial death pathway. Ann N Y Acad Sci 1010 (2003) 159-162
35. Hagen T., D'Amico G., Quintero M., et al. Inhibition of mitochondrial respiration by the anticancer agent 2-methoxyestradiol. Biochem Biophys Res Commun 322 (2004) 923-929
36. Huang P., Feng L., Oldham E.A., Keating M.J., and Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 407 (2000) 390-395
37. Pani G., Colavitti R., Bedogni B., et al. Mitochondrial superoxide dismutase: a promising target for new anticancer therapies. Curr Med Chem 11 (2004) 1299-1308